Literature DB >> 16652048

Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal.

Pascale Ondoa1, Tandakha Ndiaye Dieye, Chris Vereecken, Makhtar Camara, Abdoul Aziz Diallo, Katrien Fransen, Amber Litzroth, Souleymane Mboup, Luc Kestens.   

Abstract

Alternative, affordable, and simple assays to monitor antiretroviral therapy (ART) in resource-poor settings are needed. We have evaluated and compared a heat-denatured (HD) HIV p24 amplified enzyme-linked immunosorbent assay from Perkin-Elmer and CD38CD8 T-cell levels, determined by flow cytometry, for their capacity to predict viral load (VL) in HIV-1-infected patients from Senegal. Median fluorescence intensity (MFI) of CD38 expression on memory (CD45RO) CD8 T cells correlated better with RNA VL than HD p24 antigenemia (R = 0.576, P < 0.0001 vs R = 0.548, P < 0.0001). MFI of CD38 expression on memory CD8 T cells could predict detectable RNA VL (VL = 2.6 log10) with a sensitivity of 87% and a specificity of 74%. A comparable sensitivity (89%) could be reached for HD p24 assay, but only to predict RNA VL of more than 5 logs, which might lead to unacceptable delays in clinical decision making. The clinical use of the HD p24 assay to monitor ART in Senegal would require more comparative data about the kinetics of p24 antigen and HIV RNA in peripheral blood as well as further evaluation regarding its sensitivity toward subtype A and CRF02. MFI of CD38 expression on memory CD8 T cells appeared to be a better alternative to monitor ART in HIV-infected patients from Senegal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652048     DOI: 10.1097/01.qai.0000209901.12750.d0

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Diagnostic accuracy of ultrasensitive heat-denatured HIV-1 p24 antigen in non-B subtypes in Kampala, Uganda.

Authors:  L A Spacek; F Lutwama; H M Shihab; J Summerton; M R Kamya; A Ronald; O Laeyendecker; T C Quinn; H Mayanja-Kizza
Journal:  Int J STD AIDS       Date:  2011-06       Impact factor: 1.359

2.  HIV-1 stimulates nuclear entry of amyloid beta via dynamin dependent EEA1 and TGF-β/Smad signaling.

Authors:  Ibolya E András; Michal Toborek
Journal:  Exp Cell Res       Date:  2014-01-31       Impact factor: 3.905

3.  Immune Reconstitution During the First Year of Antiretroviral Therapy of HIV-1-Infected Adults in Rural Burkina Faso.

Authors:  Fabrice Tiba; Frans Nauwelaers; Siaka Traoré; Boubacar Coulibaly; Thierry Ouedraogo; Adama Compaoré; Hans-Georg Kräusslich; Thomas Böhler
Journal:  Open AIDS J       Date:  2012-02-24

4.  Control of viral replication after cessation of HAART.

Authors:  Ellen Van Gulck; Leo Heyndrickx; Lotte Bracke; Sandra Coppens; Eric Florence; Anne Buvé; Paul Lewi; Guido Vanham
Journal:  AIDS Res Ther       Date:  2011-02-11       Impact factor: 2.250

5.  Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Odin Goovaerts; Wim Jennes; Marguerite Massinga-Loembé; Pascale Ondoa; Ann Ceulemans; Chris Vereecken; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout.

Authors:  Robert J MacDonald; Jonathan H Shrimp; Hong Jiang; Lu Zhang; Hening Lin; Andrew Yen
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

7.  Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS).

Authors:  David M Murdoch; Melinda S Suchard; Willem D F Venter; Patrick Mhlangu; Janet S Ottinger; Charles Feldman; Annelies Van Rie; Deborah K Glencross; Wendy S Stevens; Kent J Weinhold
Journal:  AIDS Res Ther       Date:  2009-07-16       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.